CDK4 and breast cancer: With longitudinal untargeted assessment of circulating tumor DNA in metastatic HR+ breast cancer patients during CDK4/6 treatment and joint model analyses, we demonstrated that tumor fraction trajectories rather than single time point measurements provide important dynamic information on developing disease progression.